ChemotherapyFDA-approvedFirst-line

Oxaliplatin

How it works

Interferes with DNA replication and cell division, ultimately killing cancer cells, by binding to DNA and causing cross-links.

Cancer types

Colorectal CancerAll patients

Efficacy

Studies show that oxaliplatin can improve overall survival and response rates in patients with metastatic colorectal cancer.

Side effects

Severe

This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.

Evidence from research

StudyCancer typeStageEfficacy
Testing Chemo-Immunotherapy for Pancreatic CancerPancreatic Cancerphase-2Source →
Testing Lung Perfusion with Oxaliplatin for Colorectal CancerColorectal Cancerphase-1Source →
Rectal Cancer Trial Examines New Treatment CombinationColorectal Cancerphase-2Source →
Evaluating a Combination Treatment for Metastatic Colorectal Cancer in Elderly PatientsColorectal Cancerphase-2Source →
Preventing Nerve Damage in Cancer PatientsColorectal CancerpreclinicalSource →
Researchers Identify New Target for Colorectal Cancer TreatmentColorectal Cancerlab-studySource →
Nicotine Affects Colon Cancer Treatment EfficacyColorectal Cancerlab-studySource →
Blueberry Anthocyanins Enhance Chemotherapy Effectiveness in Colon Cancer CellsColorectal Cancerlab-studyThe combination of blueberry anthocyanins and oxaliplatin significantly inhibited the proliferation and colony formation of HCT116 and LOVO cells (P<0.01) and markedly suppressed tumor growth in the nude mouse xenograft model (P<0.05).Source →
Oxaliplatin-resistant colorectal cancer cells linked to specific proteinsColorectal Cancerlab-studySilencing CHGA and UCHL1 genes effectively suppressed the mobility and invasiveness of OXA-resistant HCT-116/OxR cells while promoting G1 phase cell cycle arrest and reducing ROS production and intracellular calcium concentrations.Source →
Scientists attach cancer-fighting metal to protein to deliver it to tumorsOvarian Cancerlab-studySource →
New Cancer Treatment Approach Using Moringa and 3D Printed ImplantsColorectal Cancerlab-studySource →
LAMA3 Gene May Help Colon Cancer Respond Better to OxaliplatinColorectal Cancerlab-studySource →
Comparing Chemotherapy Options for Colorectal CancerColorectal Cancerphase-3Ox resulted in a significantly improved peritoneal recurrence-free survival in CC0/1 patients (MMC=9.0 versus Ox=12.6months, P = .01).Source →
Long non-coding RNA linked to oxaliplatin resistance in colorectal cancerColorectal Cancerlab-studySource →
Oxaliplatin Side Effect Study in Colorectal Cancer PatientsColorectal Cancerphase-3Source →
New Treatment Shows Promise for Colorectal Cancer PatientsColorectal Cancerphase-1Compared with standard therapy, PIPAC-Oxaliplatin was associated with higher median good days at 6 months (181 vs 131 days; p = 0.042) and 1 year (323 vs 131 days; p = 0.032), and longer overall survival (median, 11.3 vs 5.1 months; p = 0.036).Source →
Oxaliplatin Chemotherapy Less Effective in Colorectal Cancer with High WTAP LevelsColorectal Cancerlab-studySource →
GL-V9 Enhances Effectiveness of Colorectal Cancer TreatmentColorectal Cancerlab-studySource →
Rare Side Effect of Cancer Drug: Transient Ischemic AttackColorectal CancerobservationalSource →
Combination Therapy Shows Promise Against Pancreatic CancerPancreatic Cancerlab-studySource →
Study Examines Effectiveness of S-1 and Oxaliplatin in Treating Colorectal Liver MetastasesColorectal Cancerphase-2The disease-free survival (DFS) at 3 years was 52.9% in the low-dose group.Source →
Researchers Identify Potential Biomarkers for Colorectal Cancer Resistance to OxaliplatinColorectal Cancerlab-studySource →
Chemotherapy Sensitizes Colorectal Cancers to ImmunotherapyColorectal Cancerlab-studySource →
Researchers Explore New Way to Deliver Cancer DrugColorectal CancerreviewSource →

This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.